Oral Presentation：a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer
BiologyMay 30, 2024MANILA,Philippines,May 24,2024-- Millions of women around the world continue to suffer unnecessarily from the physical and psychological effects of the menopause because of "mistaken fears"
EnergyMay 30, 2024The unique event,which is among the first global events created to build excitement for the upcoming Olympic Games,sees French andSingaporeans athletes and artists coming together to revitalise the ic
Chip TechMay 30, 2024Homegrown singer-songwriter-producer Derrick Hoh announced as Friso Brand Ambassador for 2024/25 SINGAPORE,May 24,2024--Friso,a leading nutrition formula milk brand with over 150 years of Dutch dairy
EnergyMay 30, 2024The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options.
SoftwareMay 30, 2024Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression,including in patients with PD-L1 CPS<5.
ScienceMay 30, 2024Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression,including in patients with PD-L1 CPS<5.
TechMay 30, 2024Antitumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA.
SpaceMay 30, 2024SHANGHAI,May 24,2024--Tyligand Bioscience,a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies,announced that the first patient had been dosed
Big DataMay 30, 2024BEIJING,May 24,2024-- New Oriental Education & Technology Group Inc. ("New Oriental" or the "Company") (NYSE:EDU and SEHK: 9901),a provider of private educational services in C
EnergyMay 30, 2024
Explore our curated content, stay informed about groundbreaking innovations, and journey into the future of science and tech.
© ArinstarTechnology
Privacy Policy